Back to top
more

Sight Sciences (SGHT)

(Real Time Quote from BATS)

$3.59 USD

3.59
17,189

+0.10 (2.87%)

Updated Aug 6, 2025 02:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks

by Zacks Equity Research

GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.

Zacks Equity Research

Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences (SGHT) delivered earnings and revenue surprises of 3.45% and 5.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Artivion (AORT) Lags Q1 Earnings Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of -50% and 4.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Compared to Estimates, Sight Sciences (SGHT) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences (SGHT) delivered earnings and revenue surprises of -15% and 0.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

908 Devices (MASS) delivered earnings and revenue surprises of 8.57% and 10.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Sight Sciences, Inc. (SGHT) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Sight Sciences (SGHT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sight Sciences (SGHT) delivered earnings and revenue surprises of 4.35% and 1.23%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Integer (ITGR) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Integer (ITGR) delivered earnings and revenue surprises of 5.15% and 2.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences (SGHT) delivered earnings and revenue surprises of 19.35% and 0.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Integer (ITGR) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Integer (ITGR) delivered earnings and revenue surprises of 4.84% and 0.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences (SGHT) delivered earnings and revenue surprises of -13.79% and 5.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 37.14% and 0.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sight Sciences (SGHT) to Expand in Europe With New Launch

by Zacks Equity Research

By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.

Zacks Equity Research

Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ekso Bionics (EKSO) delivered earnings and revenue surprises of 22.58% and 1.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.29% and 5.31%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of -34.85% and 2.71%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts Predict a 44.19% Upside in Sight Sciences, Inc. (SGHT): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Sight Sciences, Inc. (SGHT) points to a 44.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

All You Need to Know About Sight Sciences, Inc. (SGHT) Rating Upgrade to Buy

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

How Much Upside is Left in Sight Sciences, Inc. (SGHT)? Wall Street Analysts Think 38.78%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 38.8% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.63% and 0.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Penumbra (PEN) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of 109.09% and 4.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength?

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 16.67% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?